Rapport TherapeuticsRAPP -0.60%14 Cash Ratio is 26.64 as of Mar. 2026, which is at its 10-year median of 26.64. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,386 Biotechnology companies, Rapport Therapeutics ranks better than 95.89% on this metric.
Rapport Therapeutics has a Cash Ratio of 26.64. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Rapport Therapeutics's Cash Ratio or its related term are showing as below:
RAPP'
s Cash Ratio Range Over the Past 10 Years
Min: 16.75 Med: 26.64 Max: 45.17
Current: 26.64
During the past 4 years, Rapport Therapeutics's highest Cash Ratio was 45.17. The lowest was 16.75. And the median was 26.64.
RAPP's Cash Ratio is ranked better than 95.89% of 1386
companies
in the Biotechnology industry
Industry Median: 2.94
vs RAPP: 26.64
Rapport Therapeutics (NAS:RAPP) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Rapport Therapeutics Cash Ratio Related Terms
Rapport Therapeutics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Rapport Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rapport Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapport Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapport Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Rapport Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapport Therapeutics (RAPP) has a Cash Ratio of 26.64 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Rapport Therapeutics and its competitors. This is near median its historical median of 26.64. Over the past decade, Rapport Therapeutics' Cash Ratio has ranged from 16.75 to 45.17. According to the industry distribution chart, Rapport Therapeutics ranks #57 out of 1386 companies in the Biotechnology industry, placing it in the top 4.1%.
Is Rapport Therapeutics' Cash Ratio too high?
Rapport Therapeutics' current Cash Ratio of 26.64 is near median its 10-year median of 26.64. Over the past 10 years, this metric has ranged from a low of 16.75 to a high of 45.17. The Biotechnology industry median Cash Ratio is 2.94. Rapport Therapeutics' value of 26.64 is 806.1% above this industry median. Based on the distribution chart, Rapport Therapeutics ranks #57 out of 1386 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' Cash Ratio compare to SION and TYRA?
According to the Biotechnology industry distribution chart, Rapport Therapeutics ranks #57 out of 1386 companies for Cash Ratio. This places Rapport Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.94. Rapport Therapeutics' value of 26.64 is 806.1% above this benchmark. Historically, Rapport Therapeutics' own Cash Ratio has ranged from 16.75 to 45.17 over the past decade. While the company's 10-year median is 26.64 vs. the industry median of 2.94, Rapport Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.94, based on 1,386 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rapport Therapeutics's current Cash Ratio of 26.64 is 806.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Rapport Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapport Therapeutics's current Cash Ratio is 26.64, which is near median its own 10-year median of 26.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current Cash Ratio of 26.64. The current Cash Ratio is 26.64, which is near median its 10-year median of 26.64 and 806.1% above the Biotechnology industry median of 2.94. Rapport Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current Cash Ratio is 26.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score
Get the complete analysis for RAPP
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RAPP has been successfully added to your 
